Publications
701 results found
Angelescu I, Brugger SP, Borgan F, et al., 2021, The magnitude and variability of brain structural alterations in bipolar disorder: A double meta-analysis of 5534 patients and 6651 healthy controls, JOURNAL OF AFFECTIVE DISORDERS, Vol: 291, Pages: 171-176, ISSN: 0165-0327
- Author Web Link
- Cite
- Citations: 12
McCutcheon R, Pillinger T, Welby G, et al., 2021, Magnitude and variability of structural brain abnormalities in neuropsychiatric disease: protocol for a network meta-analysis of MRI studies, EVIDENCE-BASED MENTAL HEALTH, Vol: 24, Pages: 111-114, ISSN: 1362-0347
- Author Web Link
- Cite
- Citations: 1
Baumeister D, Ward T, Garety P, et al., 2021, Need for care, adversity exposure and perceived stress in clinical and healthy voice-hearers (vol 51, pg 1944, 2021), PSYCHOLOGICAL MEDICINE, Vol: 51, Pages: 1959-1959, ISSN: 0033-2917
Veronese M, Tuosto M, Marques TR, et al., 2021, Parametric Mapping for TSPO PET Imaging with Spectral Analysis Impulsive Response Function, MOLECULAR IMAGING AND BIOLOGY, Vol: 23, Pages: 560-571, ISSN: 1536-1632
- Author Web Link
- Cite
- Citations: 3
Baumeister D, Ward T, Garety P, et al., 2021, Need for care, adversity exposure and perceived stress in clinical and healthy voice-hearers, PSYCHOLOGICAL MEDICINE, Vol: 51, Pages: 1944-1950, ISSN: 0033-2917
- Author Web Link
- Cite
- Citations: 3
Borgan F, O'Daly O, Veronese M, et al., 2021, The neural and molecular basis of working memory function in psychosis: a multimodal PET-fMRI study, MOLECULAR PSYCHIATRY, Vol: 26, Pages: 4464-4474, ISSN: 1359-4184
- Author Web Link
- Cite
- Citations: 7
Onwordi EC, Whitehurst T, Mansur A, et al., 2021, The relationship between synaptic density marker SV2A, glutamate and N-acetyl aspartate levels in healthy volunteers and schizophrenia: a multimodal PET and magnetic resonance spectroscopy brain imaging study, Translational Psychiatry, Vol: 11, Pages: 1-9, ISSN: 2158-3188
Glutamatergic excitotoxicity is hypothesised to underlie synaptic loss in schizophrenia pathogenesis, but it is unknown whether synaptic markers are related to glutamatergic function in vivo. Additionally, it has been proposed that N-acetyl aspartate (NAA) levels reflect neuronal integrity. Here, we investigated whether synaptic vesicle glycoprotein 2 A (SV2A) levels are related to glutamatergic markers and NAA in healthy volunteers (HV) and schizophrenia patients (SCZ). Forty volunteers (SCZ n = 18, HV n = 22) underwent [11C]UCB-J positron emission tomography and proton magnetic resonance spectroscopy (1H-MRS) imaging in the left hippocampus and anterior cingulate cortex (ACC) to index [11C]UCB-J distribution volume ratio (DVR), and creatine-scaled glutamate (Glu/Cr), glutamate and glutamine (Glx/Cr) and NAA (NAA/Cr). In healthy volunteers, but not patients, [11C]UCB-J DVR was significantly positively correlated with Glu/Cr, in both the hippocampus and ACC. Furthermore, in healthy volunteers, but not patients, [11C]UCB-J DVR was significantly positively correlated with Glx/Cr, in both the hippocampus and ACC. There were no significant relationships between [11C]UCB-J DVR and NAA/Cr in the hippocampus or ACC in healthy volunteers or patients. Therefore, an appreciable proportion of the brain 1H-MRS glutamatergic signal is related to synaptic density in healthy volunteers. This relationship is not seen in schizophrenia, which, taken with lower synaptic marker levels, is consistent with lower levels of glutamatergic terminals and/or a lower proportion of glutamatergic relative to GABAergic terminals in the ACC in schizophrenia.
Kim S, Shin SH, Santangelo B, et al., 2021, Dopamine dysregulation in psychotic relapse after antipsychotic discontinuation: an [<SUP>18</SUP>F]DOPA and [<SUP>11</SUP>C]raclopride PET study in first-episode psychosis, MOLECULAR PSYCHIATRY, Vol: 26, Pages: 3476-3488, ISSN: 1359-4184
- Author Web Link
- Cite
- Citations: 12
Perry B, Osimo EF, Upthegrove R, et al., 2021, Development and external validation of the Psychosis Metabolic Risk Calculator (PsyMetRiC): a cardiometabolic risk prediction algorithm for young people with psychosis, LANCET PSYCHIATRY, Vol: 8, Pages: 589-598, ISSN: 2215-0374
- Author Web Link
- Cite
- Citations: 17
Modinos G, Richter A, Egerton A, et al., 2021, Interactions between hippocampal activity and striatal dopamine in people at clinical high risk for psychosis: relationship to adverse outcomes, NEUROPSYCHOPHARMACOLOGY, Vol: 46, Pages: 1468-1474, ISSN: 0893-133X
- Author Web Link
- Cite
- Citations: 12
Penzel N, Antonucci LA, Betz LT, et al., 2021, Association between age of cannabis initiation and gray matter covariance networks in recent onset psychosis, NEUROPSYCHOPHARMACOLOGY, Vol: 46, Pages: 1484-1493, ISSN: 0893-133X
- Author Web Link
- Cite
- Citations: 8
Rogdaki M, Devroye C, Ciampoli M, et al., 2021, Striatal dopaminergic alterations in individuals with copy number variants at the 22q11.2 genetic locus and their implications for psychosis risk: a [18F]-DOPA PET study (Jun, 2021, 10.1038/s41380-02101108-y), MOLECULAR PSYCHIATRY, ISSN: 1359-4184
Godlewska BR, Minichino A, Emir U, et al., 2021, Brain glutamate concentration in men with early psychosis: a magnetic resonance spectroscopy case-control study at 7 T., Transl Psychiatry, Vol: 11
Abnormalities in glutamate neurotransmission are linked to psychotic symptoms and cognitive dysfunction in schizophrenia. magnetic resonance spectroscopy (MRS) provides an acceptable means of measuring glutamate in the human brain but findings from patient studies at conventional magnetic field strength show considerable heterogeneity. Ultra-high-field MRS offers greater precision in glutamate measurement, particularly in delineation of glutamate from its precursor and metabolite, glutamine. This study aimed to use high-field (7 T) MRS to measure concentrations of glutamate and glutamine in three brain regions, anterior cingulate cortex (ACC), dorsolateral prefrontal cortex (DLPFC) and putamen (PUT), in young men with early psychosis. MRS was performed in 17 male participants with early psychosis and 18 healthy age-matched controls. Neurometabolite levels were calculated with unsuppressed water signal as the reference and corrected for individual grey matter, white matter and cerebrospinal fluid concentration. Cognitive function was measured with the Brief Assessment of Cognition in Schizophrenia (BACS). Compared to controls, patients with early psychosis had lower concentrations of glutamate and glutamine in ACC. No differences were apparent in the DLPFC and PUT. In patients with early psychosis, there was a highly significant correlation between glutamate concentration in ACC and performance on the BACS, though the numbers available for this analysis were small. Our finding of lower glutamate levels in ACC in patients with schizophrenia is consistent with a recent meta-analysis of 7 T studies and suggests that this abnormality is present in both patients with early psychosis and those with longer-established illness. The possible link between ACC glutamate and cognitive performance requires replication in larger studies.
Merritt K, McGuire PK, Egerton A, et al., 2021, Association of Age, Antipsychotic Medication, and Symptom Severity in Schizophrenia With Proton Magnetic Resonance Spectroscopy Brain Glutamate Level: A Mega-analysis of Individual Participant-Level Data., JAMA Psychiatry, Vol: 78, Pages: 667-681
IMPORTANCE: Proton magnetic resonance spectroscopy (1H-MRS) studies indicate that altered brain glutamatergic function may be associated with the pathophysiology of schizophrenia and the response to antipsychotic treatment. However, the association of altered glutamatergic function with clinical and demographic factors is unclear. OBJECTIVE: To assess the associations of age, symptom severity, level of functioning, and antipsychotic treatment with brain glutamatergic metabolites. DATA SOURCES: The MEDLINE database was searched to identify journal articles published between January 1, 1980, and June 3, 2020, using the following search terms: MRS or magnetic resonance spectroscopy and (1) schizophrenia or (2) psychosis or (3) UHR or (4) ARMS or (5) ultra-high risk or (6) clinical high risk or (7) genetic high risk or (8) prodrome* or (9) schizoaffective. Authors of 114 1H-MRS studies measuring glutamate (Glu) levels in patients with schizophrenia were contacted between January 2014 and June 2020 and asked to provide individual participant data. STUDY SELECTION: In total, 45 1H-MRS studies contributed data. DATA EXTRACTION AND SYNTHESIS: Associations of Glu, Glu plus glutamine (Glx), or total creatine plus phosphocreatine levels with age, antipsychotic medication dose, symptom severity, and functioning were assessed using linear mixed models, with study as a random factor. MAIN OUTCOMES AND MEASURES: Glu, Glx, and Cr values in the medial frontal cortex (MFC) and medial temporal lobe (MTL). RESULTS: In total, 42 studies were included, with data for 1251 patients with schizophrenia (mean [SD] age, 30.3 [10.4] years) and 1197 healthy volunteers (mean [SD] age, 27.5 [8.8] years). The MFC Glu (F1,1211.9 = 4.311, P = .04) and Glx (F1,1079.2 = 5.287, P = .02) levels were lower in patients than in healthy volunteers, and although creatine levels appeared lower in patients, the difference was not significant (F1,1395.9&thi
Bloomfield MAP, Petrilli K, Lees R, et al., 2021, The Effects of Acute Δ<SUP>9</SUP>-Tetrahydrocannabinol on Striatal Glutamatergic Function: A Proton Magnetic Resonance Spectroscopy Study, BIOLOGICAL PSYCHIATRY-COGNITIVE NEUROSCIENCE AND NEUROIMAGING, Vol: 6, Pages: 660-667, ISSN: 2451-9022
- Author Web Link
- Cite
- Citations: 2
McCutcheon RA, Brown K, Nour MM, et al., 2021, Dopaminergic organization of striatum is linked to cortical activity and brain expression of genes associated with psychiatric illness, SCIENCE ADVANCES, Vol: 7, ISSN: 2375-2548
- Author Web Link
- Cite
- Citations: 8
Borgan F, Kokkinou M, Howes O, 2021, The Cannabinoid CB<sub>1</sub> Receptor in Schizophrenia, BIOLOGICAL PSYCHIATRY-COGNITIVE NEUROSCIENCE AND NEUROIMAGING, Vol: 6, Pages: 646-659, ISSN: 2451-9022
- Author Web Link
- Cite
- Citations: 9
Borgan F, Veronese M, Marques TR, et al., 2021, Association between cannabinoid 1 receptor availability and glutamate levels in healthy controls and drug-free patients with first episode psychosis: a multi-modal PET and 1H-MRS study, EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, Vol: 271, Pages: 677-687, ISSN: 0940-1334
- Author Web Link
- Cite
- Citations: 6
Beck K, Hindley G, Borgan F, et al., 2021, The effect of ketamine on psychopathology and implications for understanding schizophrenia and its therapeutic use: a meta-analysis, Publisher: CAMBRIDGE UNIV PRESS, Pages: S237-S237, ISSN: 2056-4724
Muratib F, Mizuno Y, Figueiredo IC, et al., 2021, Dissection of neuroinflammation in schizophrenia, Publisher: CAMBRIDGE UNIV PRESS, Pages: S274-S275, ISSN: 2056-4724
Beck K, Arumuham A, Santangelo B, et al., 2021, N-Methyl-D-Aspartate Receptor binding in First-Episode Psychosis: A PET brain imaging study, Publisher: CAMBRIDGE UNIV PRESS, Pages: S7-S7, ISSN: 2056-4724
- Author Web Link
- Cite
- Citations: 1
McCutcheon RA, Pillinger T, Rogdaki M, et al., 2021, Glutamate connectivity associations converge upon the salience network in schizophrenia and healthy controls, TRANSLATIONAL PSYCHIATRY, Vol: 11, ISSN: 2158-3188
- Author Web Link
- Cite
- Citations: 6
Rogdaki M, Devroye C, Ciampoli M, et al., 2021, Striatal dopaminergic alterations in individuals with copy number variants at the 22q11.2 genetic locus and their implications for psychosis risk: a [18F]-DOPA PET study, MOLECULAR PSYCHIATRY, ISSN: 1359-4184
- Author Web Link
- Cite
- Citations: 9
Halff EF, Cotel M-C, Natesan S, et al., 2021, Effects of chronic exposure to haloperidol, olanzapine or lithium on SV2A and NLGN synaptic puncta in the rat frontal cortex, BEHAVIOURAL BRAIN RESEARCH, Vol: 405, ISSN: 0166-4328
- Author Web Link
- Cite
- Citations: 7
Veronese M, Tuosto M, Marques TR, et al., 2021, Parametric mapping for TSPO PET imaging with spectral analysis impulsive response function, Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI), Publisher: SOC NUCLEAR MEDICINE INC, ISSN: 0161-5505
Howes O, Onwordi E, Whitehurst T, et al., 2021, Synaptic Dysfunction in Schizophrenia and the Effects of Treatment: Complementary in Vivo Clinical and Pre-clinical Studies, Publisher: ELSEVIER SCIENCE INC, Pages: S34-S35, ISSN: 0006-3223
Maslej MM, Furukawa TA, Cipriani A, et al., 2021, Individual Differences in Response to Antidepressants A Meta-analysis of Placebo-Controlled Randomized Clinical Trials, JAMA PSYCHIATRY, Vol: 78, Pages: 490-497, ISSN: 2168-622X
- Author Web Link
- Cite
- Citations: 18
Howes OD, Mehta MA, 2021, Challenges in CNS drug development and the role of imaging, PSYCHOPHARMACOLOGY, Vol: 238, Pages: 1229-1230, ISSN: 0033-3158
- Author Web Link
- Cite
- Citations: 9
McQueen G, Sendt K-V, Gillespie A, et al., 2021, Changes in Brain Glutamate on Switching to Clozapine in Treatment-Resistant Schizophrenia, SCHIZOPHRENIA BULLETIN, Vol: 47, Pages: 662-671, ISSN: 0586-7614
- Author Web Link
- Cite
- Citations: 25
Veronese M, Santangelo B, Jauhar S, et al., 2021, A potential biomarker for treatment stratification in psychosis: evaluation of an [<SUP>18</SUP>F] FDOPA PET imaging approach, NEUROPSYCHOPHARMACOLOGY, Vol: 46, Pages: 1122-1132, ISSN: 0893-133X
- Author Web Link
- Cite
- Citations: 25
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.